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State-of-the-art, implantable, dual-chamber cardiac devices provide useful diagnostic
information, including the number and duration of automatic-mode switch episodes
in cases of atrial tachycardia and atrial ﬁbrillation encountered in clinical practice.
However, to acquire accurate diagnostic information, special attention must be paid to
the device settings; to the presence or absence of ventriculoatrial conduction, which,
when present, often represents repetitive non-reentrant synchrony (RNRVAS) or pace-
maker-mediated tachycardia; to the post-ventricular atrial-blanking period and atrial
sensitivity; and to the sensing of far-ﬁeld R waves (FFRW) in the atrial channel.
Physicians should be careful about the information gathered during the monitoring of
patients with implantable devices.
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Implantable cardiac monitoring devices are a useful
and reliable means of diagnosing atrial tachycardia and
atrial ﬁbrillation (AT/AF) in clinical practice. The yearly
incidence of symptomatic or asymptomatic paroxysmalrt Rhythm Society. PublishAT/AF diagnosed by pacemakers may exceed 50% [1–6].
Current guidelines recommend long-term anticoagulation
therapy in patients with non-rheumatic, paroxysmal, or
permanent AF and risk factors. The lowest atrial rate and
duration of AT/AF (as detected by implantable monitoring
devices) associated with an increased risk of thromboem-
bolisms have not yet been deﬁned. In one study, brief
episodes of paroxysmal AF (often o30 s in duration)
recorded during a mean of 22.6 h of ambulatory electro-
cardiographic monitoring were found to be associateded by Elsevier B.V. All rights reserved.
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the lesions were cortical, in particular, and the ﬁndings
were consistent with embolisms [7]. The importance
of very brief episodes of AT/AF was conﬁrmed by the
asymptomatic atrial ﬁbrillation and Stroke Evaluation in
pacemaker patients and the atrial ﬁbrillation Reduction
atrial pacing Trial (ASSERT) [8]. In that trial, over a mean
follow-up period of 2.8 years (1) episodes of AT/AF lasting
46 min at a rate 4190 bpm were detected by the atrial
high-rate episode (AHRE) function in 36% of 2580 pace-
maker or implantable deﬁbrillator recipients who had no
history of AT/AF before device implantation, and (2)
patients with AT/AF detected by the AHRE function were
found to have a 2.5-fold higher incidence of ischemic
strokes or systemic embolisms than those without [8,9].
Notably, among pacemaker recipients without a history
of AT/AF, 35% of all strokes or systemic embolisms
were preceded by AT/AF detected by the pacemaker [9].
Therefore, an accurate identiﬁcation of AT/AF allows the
planning of optimal antiarrhythmic and antithrombotic
therapy [3].
2. Detection methods in implantable monitoring device
State-of-the-art, implantable, dual-chamber cardiac
devices provide useful diagnostic information, including
the numbers and duration of automatic mode switch
(AMS) episodes upon detection of AT/AF. However, to
collect accurate diagnostic information, special attention
must be paid to the following factors: the device settings;
the presence versus absence of ventriculoatrial (VA) conduc-
tion, which, when present, often represents repetitive non-
reentrant synchrony (RNRVAS) or pacemaker-mediated
tachycardia (PMT); the post-ventricular atrial-blanking
period (PVAB) and atrial sensitivity; and the sensing of
far-ﬁeld R waves (FFRW) in the atrial channel. Preventing
FFRW sensing by the atrial channel is challenging since it
is inversely correlated with the duration of the PVAB and
with the atrial sensitivity. Furthermore, the presence of
VA conduction may cause RNRVAS or PMT. Although
FFRW sensing, RNRVAS, and PMT are not atrial tachyar-
rhythmias, they (a) are considered AT/AF episodes by
implantable monitoring devices, (b) may be the source
of inaccurate diagnostic information and inappropriate
AMS from DDD to DDI or VVI mode, and (c) may trigger
AT/AF or cause pacemaker syndrome [10–20].
This review focuses on the incidence and character-
istics of non-AT/AF events, such as RNRVAS and FFRW
oversensing, which can be detected by implantable mon-
itoring devices.
3. Prevalence of AT/AF in recipients of implantable
cardiac devices
The reported incidence of symptomatic or asympto-
matic AT/AF, detected by AHRE in recipients of implan-
table monitoring devices, is variable and as high as 51%
per year among populations that included patients with
or without previously documented AT/AF, and with or
without organic heart disease [1–6]. One explanation for
the variable incidence among studies is the criterion ofAT/AF duration, which ranged between Z30 s and Z1 h,
depending on the study protocol [1–5]. In the ASSERT
trial, AT/AF was arbitrarily deﬁned as lasting for 46 min
[8,9]. The duration of follow-ups also varied widely
between 29 days and 27 months among studies [1–5].
Finally, in most previous studies, the AT/AF was deﬁned
on the basis of the numbers of AHRE or of AMS, with or
without the application of the atrial overdrive pacing
algorithm. Thus, the incidence of AT/AF detected by
implantable devices depends on the following factors:
(a) the deﬁnition of AT/AF, (b) the presence or absence of
a history of AT/AF before pacemaker implantation, (c) the
cumulative percentage of atrial (Cum% Ap) or ventricular
(Cum% Vp) pacing, (d) the ventricular pacing site, (e) the
presence or absence of sinus node disease or atrio-
ventricular (AV) block as a pacing indication, and (f) the
AHRE settings, which include the atrial sensitivity and
detection rate.
4. Variables inﬂuencing the detection of AT/AF by
implantable devices
4.1. Far-ﬁeld R-wave sensing
FFRW sensing is deﬁned as the sensing of ventricular
potentials in the absence of atrial contraction in the atrial
channel (Fig. 1). The intracardiac electrogram (iEGM)
channel in the ﬁgure shows a sensed atrial event after
ventricular pacing, which may represent retrograde atrial
activation of a paced ventricular event or FFRW sensing
without atrial depolarization, with the latter being con-
ﬁrmed in this case. The implantable device counted 1
sensed FFRW event in the atrial channel, which exceeded
the programmed atrial rate of AHRE, and 1 normal atrial
paced or sensed event, resulting in double counts of atrial
activation for a single paced ventricular event. If the rate
of paced atrial events and sensed FFRW exceeds the AMS
detection rate, the latter is activated, and the device
erroneously diagnoses AT/AF. Fig. 2 shows the disadvan-
tages of FFRW sensing by a dual-chamber implantable
device. The erroneous detection of AT/AF causes inap-
propriate AMS, resulting in incorrect conclusions, such as
AHRE and AF burden, as well the automatic conversion of
the pacing mode to DDI or VVI, which may cause pace-
maker syndrome due to AV dyssynchrony, or induce new
episodes of AF. Furthermore, in recipients of implantable
cardioverter deﬁbrillators, the delivery of antitachycardia
pacing or shocks may be delayed, and in patients under-
going cardiac resynchronization, the treatment effects
may be decreased by an insufﬁcient percentage of ven-
tricular pacing.
The atrial pacing site inﬂuences the detection of AT/AF
by the atrial channel of dual-chamber devices. The right
atrial appendage (RAA) is unsuitable for the prevention
of AT/AF, because it lengthens the inter- or intra-atrial
conduction times and increases the dispersion of atrial
refractoriness [21]. Instead, low right atrial septal (LRAS)
pacing has been recommended [22] although it has not
been tested in a randomized clinical trial [23]. Figs. 3 and 4
show a chest roentgenogram and electrocardiogram,
respectively, of a dual-chamber pacemaker recipient, in
Fig. 2. Representative case of far-ﬁeld R-wave sensing. Arrows shows
far-ﬁeld R wave oversensing in atrial channel. With permission of
Ref. [33].
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Fig. 1. Adverse effects of far-ﬁeld R-wave sensing in dual-chamber implantable devices. Far-ﬁeld R-wave sensing may cause the erroneous detection of
AT/AF and inappropriate AMS, yielding inaccurate diagnostic information, such as AHRE, AF burden and numbers of AMS; it may also cause pacemaker
syndrome due to AV dyssynchrony or development of new AF. In addition, antitachycardia pacing or ICD shock therapy may be delayed, and the
cumulative percent ventricular pacing in recipients of cardiac resynchronization therapy devices may be decreased, lowering their therapeutic effects.
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right ventricular lead was implanted in the septum. The
tip of the LRAS pacing lead was located inferiorly and
posteriorly (Fig. 3), and the P wave was negative in the
inferior leads and in leads I, V5, and V6 (Fig. 4). However,
because the LRAS region is closer to the ventricle than the
RAA, it is associated with a higher likelihood of FFRW
sensing [22–24], although the prevalence and character-
istics of FFRW sensing associated with LRAS pacing have
not been formally studied. Preventing sensing of FFRW
in the atrium is a major challenge since it is inversely
correlated with the duration of the PVAB and with the
atrial sensitivity setting.
The atrial sensing function is inﬂuenced by the use of
various atrial pacing/sensing leads. For example, the
interelectrode spacing of bipolar atrial leads determines,
in part, the likelihood of FFRW oversensing [14,25–27],which tends to decrease with the reduction in the spacing
[25–27]. In the RAA, at a sensitivity of 0.3 mV, FFRW was
sensed in 30% of recipients of leads with 10-mm inter-
electrode spacing, and in none of the patients receiving
leads with tip-ring electrodes separated by 1.1 mm
[25,26]. The capture and sensing characteristics of these
new leads were similar and remained stable over a long
period of time [25–27]. Thus, a closer interelectrode
spacing of the atrial lead lowered the likelihood of sensed
FFRW, without interfering with pacing.4.2. Repetitive non-reentrant VA synchrony
Repetitive non-reentrant VA synchrony (RNRVAS) is
not a rare occurrence with dual-chamber implantable
devices [20,28–31]. Most previously described cases of
RNRVAS, which accelerate the pacing rate, have been
associated with sensor-driven DDDR pacing [28,29]. This
form of VA synchrony is usually associated with the
programming of long AV intervals and relatively high
atrial rates during DDD or DDDR pacing, and it is found to
be greatly facilitated by atrial overdrive pacing, which is
achieved by algorithms such as AF suppression and atrial
referential pacing (APP). An example of RNRVAS is shown
in Fig. 5. The disadvantages of RNRVAS include (1) loss of
optimal AV delay, (2) inappropriate increase in ventricular
pacing rate, (3) triggering of atrial arrhythmias, and (4)
inaccurate AHRE. Because of its adverse effects on ven-
tricular function, unnecessary RV pacing must be mini-
mized; in dual-chamber implantable devices, this can be
achieved by programming a long AV delay, particularly, in
the presence of sinus node disease and preserved AV
conduction. Since the AHRE function offered by implan-
table monitoring devices provides useful diagnostic infor-
mation, which facilitates therapeutic decisions, including
whether or not to administer anticoagulation therapy for
Fig. 3. Chest radiograph of a dual-chamber pacemaker recipient. The atrial lead is located in low right atrial septal site, conﬁrmed by the inferior and
posterior directions on the lateral projection. Red color circle shows the tip of atrial lead, and yellow color circle shows the tip of ventricular lead. With
permission of Ref. [33]. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Electrocardiogram recorded in a patient paced from the low right atrial septum and intrinsic QRS complex. The P wave is negative in the inferior
leads and in leads I, V5, and V6. The arrows point to the atrial stimulus artifacts. With permission of Ref. [33].
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to erroneous diagnosis and inappropriate treatment.
The induction of RNRVAS by atrial overdrive pacing is
explained as follows: (1) the retrograde P wave after
ventricular pacing falls within the post-ventricular atrial
refractory period (PVARP); (2) the atrial overdrive pacing
algorithm is activated immediately after the sensed retro-
grade P wave; (3) since the interval between the sensed
retrograde P wave and the next atrial event initiated by
the atrial overdrive pacing algorithm is very short, the
atrial pacing stimulus falls inside the atrial refractory
period and fails to capture the atrium; (4) ventricular
pacing after an AV interval long enough for the recovery
of the atrial myocardium allows repetitive VA conduc-
tion and perpetuation of RNRVAS. Therefore, RNRVAS isgenerally observed when (1) VA conduction and retro-
grade P waves sensed within the PVARP after ventricular
pacing are present, thereby triggering atrial overdrive
pacing, and (2) a relatively long AV interval has been
programmed, to limit the cumulative percentage of ven-
tricular pacing, particularly in sick sinus syndrome
[20,30,31]. RNRVAS could theoretically be prevented by
inhibiting VA conduction, or ineffective atrial pacing by a
high atrial pacing rate, or both. Antiarrhythmic drugs
administered to suppress paroxysmal AF may prolong
the atrial refractory period and increase the likelihood of
RNRVAS by increasing the percentage of ineffective atrial
pacing events.
Furthermore, high atrial pacing rates, induced by the
use of the atrial rate responsive function or the atrial
Fig. 5. Representative example of stored iEGM of RNRVAS. The retrograde P wave after ventricular pacing falls within the PVARP. The AF suppression
algorithm triggers atrial overdrive pacing immediately after the sensed retrograde P wave. However, since the interval between that of the sensed P wave
and the next paced atrial event is very short, the stimulus falls in the atrial myocardial refractory period and fails to capture the atrium. Ventricular
pacing after an AV interval long enough to allow atrial recovery is associated with repetitive VA conduction and sustained RNRVAS.
Top tracing¼marker chains; bottom tracing¼ iEGM.
V¼paced ventricular event; A¼paced atrial event; P¼sensed atrial event; ¼sensed atrial event falling within the PVARP; R¼sensed ventricular event;
Atip–Aring¼bipolar atrial recording between tip and ring of the atrial lead. With permission of Ref. [30].
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Fig. 6. Episodes of AHRE recorded by iEGM with the atrial overdrive
pacing algorithm ‘‘ON’’ versus ‘‘OFF.’’ A total of 181 (69%) AHRE was
observed in the atrial overdrive pacing algorithm ‘‘ON’’ group. Of those,
109 of 181 episodes (60%) were RNRVAS and 72 episodes (40%) were AF.
A total of 76 (30%) AHRE were observed in the atrial overdrive pacing
algorithm ‘‘OFF’’ group, all of which were episodes of AF. With permis-
sion of Ref. [20].
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increase the likelihood of ineffective atrial pacing events;
these events, in turn, induce ventricular pacing in the
absence of intrinsic AV conduction, including after a
retrograde P wave sensed inside the PVARP.
We have recently observed that RNRVAS, which is
stored as AHRE in the pacemaker memory, is induced by
the atrial overdrive pacing algorithm for the prevention of
AT/AF [20,30] and by rate-adaptive DDIR pacing in
patients permanently paced for sinus node dysfunction
[31]. The initiation of RNRVAS is usually due to (1) VA
conduction and retrograde P waves sensed within the
PVARP, (2) additional programming of rate-responsive
or atrial overdrive pacing for the prevention of AF, and
(3) programming of a long AV interval.
We studied the incidence and characteristics of
RNRVAS in 39 recipients of dual-chamber pacemakers
(mean age¼79.776.6 years); these patients had no
history of AT/AF, and their pacemakers were set to AHRE
at 4190 bpm, in the DDD mode [20]. The atrial overdrive
pacing algorithm was randomly set at ‘‘ON’’ in 19 and
‘‘OFF’’ in 20 patients. AHRE was detected in 20 patients
(51%), with 15 of them having AT/AF and 8 having
RNRVAS; all these patients belonged to the group with
the atrial overdrive pacing set at ‘‘ON.’’ A total of 257 of
1528 episodes of AHRE were analyzed, including 181 and
76 episodes in the groups with the atrial overdrive pacing
settings of ‘‘ON’’ and ‘‘OFF,’’ respectively. Among the 181
episodes detected in the group with the ‘‘ON’’ setting of
atrial overdrive pacing, 72 (40%) were RNRVAS, whereas
100% of the episodes in the groups with the ‘‘OFF’’ setting
of the atrial overdrive pacing were AT/AF (Fig. 6). The
detection of RNRVAS was closely associated with a high
Cum% Ap. With the atrial overdrive pacing algorithm
activated, the speciﬁcity of AT/AF detection by AHRE
was 40%, as against 100% in its absence. In addition, most
episodes of RNRVAS lasted r10 min (Fig. 7) [20]. Thus,
AT/AF was common in pacemaker recipients without a
history of AT/AF. The increase in Cum% Ap associated with
the use of the AF suppression algorithm appears to beclosely associated with the incidence of RNRVAS, i.e., non-
AT/AF, as detected by AHRE. These observations suggest
that close attention should be paid to the detection of AT/
AF by AHRE and the use of iEGM in particular [20,30,31].
5. Optimal setting of atrial sensitivity and post
ventricular atrial blanking
An optimal setting of the atrial sensitivity is crucial to
an accurate detection of AT/AF by implantable dual-
chamber monitoring devices. The setting of a low atrial
sensitivity decreases the likelihood of FFRW oversensing
as well as the chances of detecting AT/AF; this is because
undersensing of the atrial electrogram during ongoing
tachyarrhythmia may lead to the underestimation of the
incidence of clinical AT/AF. Conversely, the setting of a
high atrial sensitivity increases the chances of detecting
AT/AF and the likelihood of FFRW oversensing, which can
lead to the overestimation of the incidence of clinical
AT/AF. While an optimal setting of atrial sensitivity remains
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H. Abe / Journal of Arrhythmia 28 (2012) 19–2524unclear, ao0.5 mV setting is generally recommended
for recipients of implantable devices who have a history
of AF.
Increasing the duration of PVAB might be an effective
means of preventing FFRW oversensing in the atrial
channel. However, this narrows the search window of
atrial sensing and shortens the window of AT/AF detec-
tion, which might decrease the likelihood of detecting
AT/AF. Conversely, a short PVAB widens the search win-
dow of atrial sensing and of AT/AF detection, thereby
decreasing the speciﬁcity of AT/AF detection. In clinical
practice, a setting of þ25 ms between the ventricular
pacing spike and FFRW sensing is generally recommended
for the PVAB [23].
6. Conclusions
Implantable monitoring devices have become highly
useful diagnostic tools for AT/AF [32]. However, the
accuracy of the obtained diagnostic information is inﬂu-
enced by several factors, including the presence of non-
AT/AF events, such as RNRVAS or PMT, caused by VA
conduction or by suboptimal settings of the atrial sensi-
tivity and PVAB duration.
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